There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Unity Biotechnology (UBX – Research Report) and Rockwell Med (RMTI – Research Report) with bullish sentiments.
Unity Biotechnology (UBX)
H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on Unity Biotechnology today and set a price target of $10.00. The company’s shares closed last Wednesday at $2.41.
According to TipRanks.com, Caufield is a 5-star analyst with an average return of
Currently, the analyst consensus on Unity Biotechnology is a Moderate Buy with an average price target of $6.00.
See the top stocks recommended by analysts >>
Rockwell Med (RMTI)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Rockwell Med, with a price target of $11.00. The company’s shares closed last Wednesday at $1.85.
According to TipRanks.com, Selvaraju has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Rockwell Med has an analyst consensus of Moderate Buy, with a price target consensus of $11.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on UBX:
- UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
- Unity Biotechnology reports Q2 EPS (85c), consensus (86c)
- UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates
- Is UBX a Buy, Before Earnings?
